Explanation:

United States (US) Food and Drug Administration (FDA) has approved new drug-Pretomanid for treating drug-resistant strain of Tuberculosis (TB).

• Pretomanid is novel compound developed by New York-based non-profit organisation TB Alliance.
• It is used alongside two other antibiotics (bedaquiline and linezolid) to treat extremely drug-resistant strain of tuberculosis.
• This three-drug regimen is collectively known as BPaL regimen and it can cure highly drug-resistant strains of tuberculosis by drastically shortening treatment period.